Bruker: Still Not A Healthy Diagnosis

Bruker: Still Not A Healthy Diagnosis Summary Bruker was seeing an appealing situation in 2025 after a strange year in 2024. Its aggressive M&A spree, funded by rising net debt and a $600M mandatory convertible preferred issuance, heightens financial risk. Despite initial optimism, execution issues and deteriorating fundamentals have led me to actively reduce my position in Bruker. The risk-reward profile has worsened, as shares have rebounded modestly but underlying business performance remains concerning. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~230 words